OBJECTIVE: To investigate antibodies to complement 1q (anti-C1q) and investigate the correlation between anti-C1q titres and renal disease in systemic lupus erythematosus (SLE). METHODS: 151 SLE patients were studied. In patients with biopsy proven lupus nephritis (n = 77), activity of renal disease was categorised according to the BILAG renal score. Sera were tested for anti-C1q by enzyme immunoassay. Serum samples were randomly selected from 83 SLE patients who had no history of renal disease, and the positive and negative predictive value of the antibodies was studied. RESULTS: Patients with active lupus nephritis (BILAG A or B) had a higher prevalence of anti-C1q than those with no renal disease (74% v 32%; relative risk (RR) = 2.3 (95% confidence interval, 1.6 to 3.3)) (p<0.0001). There was no significant difference in anti-C1q prevalence between SLE without nephritis and SLE with non-active nephritis (BILAG C or D) (32% v 53%, p = 0.06) or between active and non-active nephritis (74% v 53%, p = 0.06). Patients with nephritis had higher anti-C1q levels than those without nephritis (36.0 U/ml (range 4.9 to 401.0) v 7.3 U/ml (4.9 to 401.0)) (p<0.001). Anti-C1q were found in 33 of 83 patients (39%) without history of renal disease. Nine of the 33 patients with anti-C1q developed lupus nephritis. The median renal disease-free interval was nine months. One patient with positive anti-C1q was diagnosed as having hypocomplementaemic urticarial vasculitis syndrome during follow up. CONCLUSIONS: Anti-C1q in SLE are associated with renal involvement. Monitoring anti-C1q and their titres in SLE patients could be important for predicting renal flares.
OBJECTIVE: To investigate antibodies to complement 1q (anti-C1q) and investigate the correlation between anti-C1q titres and renal disease in systemic lupus erythematosus (SLE). METHODS: 151 SLEpatients were studied. In patients with biopsy proven lupus nephritis (n = 77), activity of renal disease was categorised according to the BILAG renal score. Sera were tested for anti-C1q by enzyme immunoassay. Serum samples were randomly selected from 83 SLEpatients who had no history of renal disease, and the positive and negative predictive value of the antibodies was studied. RESULTS:Patients with active lupus nephritis (BILAG A or B) had a higher prevalence of anti-C1q than those with no renal disease (74% v 32%; relative risk (RR) = 2.3 (95% confidence interval, 1.6 to 3.3)) (p<0.0001). There was no significant difference in anti-C1q prevalence between SLE without nephritis and SLE with non-active nephritis (BILAG C or D) (32% v 53%, p = 0.06) or between active and non-active nephritis (74% v 53%, p = 0.06). Patients with nephritis had higher anti-C1q levels than those without nephritis (36.0 U/ml (range 4.9 to 401.0) v 7.3 U/ml (4.9 to 401.0)) (p<0.001). Anti-C1q were found in 33 of 83 patients (39%) without history of renal disease. Nine of the 33 patients with anti-C1q developed lupus nephritis. The median renal disease-free interval was nine months. One patient with positive anti-C1q was diagnosed as having hypocomplementaemic urticarial vasculitis syndrome during follow up. CONCLUSIONS: Anti-C1q in SLE are associated with renal involvement. Monitoring anti-C1q and their titres in SLEpatients could be important for predicting renal flares.
Authors: L Horváth; L Czirják; B Fekete; L Jakab; T Pozsonyi; L Kalabay; L Romics; K Miklós; L Varga; Z Prohászka; A Szakács; E Nagy; M R Daha; G Füst Journal: Clin Exp Rheumatol Date: 2001 Nov-Dec Impact factor: 4.473
Authors: G Moroni; M Trendelenburg; N Del Papa; S Quaglini; E Raschi; P Panzeri; C Testoni; A Tincani; G Banfi; G Balestrieri; J A Schifferli; P L Meroni; C Ponticelli Journal: Am J Kidney Dis Date: 2001-03 Impact factor: 8.860
Authors: Iva Gunnarsson; Birgitta Sundelin; Mikael Heimbürger; Jan Forslid; Ronald van Vollenhoven; Ingrid Lundberg; Stefan H Jacobson Journal: J Rheumatol Date: 2002-04 Impact factor: 4.666
Authors: G J Arason; R Kolka; A B Hreidarsson; H Gudjonsson; P M Schneider; L Fry; A Arnason Journal: Clin Exp Immunol Date: 2005-06 Impact factor: 4.330
Authors: B Namjou; C Gray-McGuire; A L Sestak; G S Gilkeson; C O Jacob; J T Merrill; J A James; E K Wakeland; Q-Z Li; C D Langefeld; J Divers; J Ziegler; K L Moser; J A Kelly; K M Kaufman; J B Harley Journal: Genes Immun Date: 2009-05-14 Impact factor: 2.676